Early defect of transforming growth factor β1 formation in Huntington's disease

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 3, 2011, Pages 555-571

  Battaglia, Giuseppe ^a   Cannella, Milena ^a   Riozzi, Barbara ^a   Orobello, Sara ^a   Maat Schieman, Marion L ^b   Aronica, Eleonora ^c   Busceti, Carla Letizia ^a   Ciarmiello, Andrea ^d   Alberti, Silvia ^a   Amico, Enrico ^a   Sassone, Jenny ^e   Sipione, Simonetta ^f   Bruno, Valeria ^a,g   Frati, Luigi ^h   Nicoletti, Ferdinando ^a,g   Squitieri, Ferdinando ^a  

^a IRCCS NEUROMED   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^f UNIVERSITY OF ALBERTA   (Canada)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Brain cortex; Huntington's disease; Neurodegeneration; Neurodysfunction; Peripheral markers; Transforming growth factor

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; AMINO ACID; FUSED HETEROCYCLIC RINGS; HD PROTEIN, HUMAN; METABOTROPIC RECEPTOR; NERVE PROTEIN; NUCLEAR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANIMAL; ARTICLE; ASTROCYTE; BLOOD; BRAIN; C57BL MOUSE; CADAVER; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETICS; HUMAN; HUNTINGTON CHOREA; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADULT; AGED; AMINO ACIDS; ANIMALS; ASTROCYTES; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; POSITRON-EMISSION TOMOGRAPHY; POSTMORTEM CHANGES; RECEPTORS, METABOTROPIC GLUTAMATE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

MUS;

EID: 79953298589     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01011.x     Document Type: Article

References (93)

1. Sathasivam K, Hobbs C, Turmaine M, et al Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet. 1999; 8: 813-22.
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72: 971-83.
3. Vonsattel JP, Myers RH, Stevens TJ, et al Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985; 44: 559-77.
4. de la Monte SM, Vonsattel JP, Richardson EPJr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol. 1988; 47: 516-25.
5. Beal MF, Kowall NW, Ellison DW, et al Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986; 321: 168-71.
6. Ross CA. Huntington's disease: new paths to pathogenesis. Cell. 2004; 118: 4-7.
7. Sapp E, Kegel KB, Aronin N, et al Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001; 60: 161-72.
8. Pavese N, Gerhard A, Tai YF, et al Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006; 66: 1638-43.
9. Tai YF, Pavese N, Gerhard A, et al Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007; 130: 1759-66.
10. Shin JY, Fang ZH, Yu ZX, et al Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol. 2005; 171: 1001-12.
11. Krieglstein K, Henheik P, Farkas L, et al Glial cell line-derived neurotrophic factor requires transforming growth factor-beta for exerting its full neurotrophic potential on peripheral and CNS neurons. J Neurosci. 1998; 18: 9822-34.
12. Bruno V, Battaglia G, Casabona G, et al Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci. 1998; 18: 9594-600.
13. Lee HG, Ueda M, Zhu X, et al Ectopic expression of phospho-Smad2 in Alzheimer's disease: uncoupling of the transforming growth factor-beta pathway J Neurosci Res. 2006; 84: 1856-61.
14. Tesseur I, Zou K, Esposito L, et al Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest. 2006; 116: 3060-9.
15. Ueberham U, Ueberham E, Gruschka H, et al Altered subcellular location of phosphorylated Smads in Alzheimer's disease. Eur J Neurosci. 2006; 24: 2327-34.
16. Chalmers KA, Love S. Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J Neuropathol Exp Neurol. 2007; 66: 158-67.
17. Tesseur I, Wyss-Coray T. A role for TGF-beta signaling in neurodegeneration: evidence from genetically engineered models. Curr Alzheimer Res. 2006; 3: 505-13.
18. Brionne TC, Tesseur I, Masliah E, et al Loss of TGF-beta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron. 2003; 40: 1133-45.
19. Sortino MA, Chisari M, Merlo S, et al Glia mediates the neuroprotective action of estradiol on beta-amyloid-induced neuronal death. Endocrinology. 2004; 145: 5080-86.
20. D'Onofrio M, Cuomo L, Battaglia G, et al Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J Neurochem. 2001; 78: 435-45.
21. Corti C, Battaglia G, Molinaro G, et al The use of knockout mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J Neurosci. 2007; 27: 8297-308.
22. Cha JH, Kosinski CM, Kerner JA, et al Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA. 1998; 95: 6480-5.
23. Squitieri F, Gellera C, Cannella M, et al Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain. 2003; 126: 946-55.
24. Langbehn DR, Brinkman RR, Falush D, et al A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65: 267-77.
25. Huntington Study Group. The Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11: 136-42.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 2: 189-98.
27. Ciarmiello A, Cannella M, Lastoria S, et al Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med. 2006; 47: 215-22.
28. Myers RH, Sax DS, Koroshetz WJ, et al Factors associated with slow progression in Huntington's disease. Arch Neurol. 1991; 48: 800-4.
29. Marder K, Zhao H, Myers RH, et al Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000; 54: 452-8.
30. Squitieri F, Ciarmiello A, Di Donato S, et al The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction. [Review] Eur J Neurol. 2006; 13: 408-15.
31. Ciammola A, Sassone J, Cannella M, et al Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B: 574-7.
32. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000; 11: 133-45.
33. Mangiarini L, Sathasivam K, Seller M, et al Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996; 87: 493-506.
34. Slow EJ, van Raamsdonk J, Rogers D, et al Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003; 12: 1555-67.
35. Katoh-Semba R, Asano T, Ueda H, et al Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J. 2002; 16: 1328-30.
36. Squitieri F, Ciammola A, Colonnese C, et al Neuroprotective effects of riluzole in Huntington's disease. Eur J Nucl Med Mol Imaging. 2008; 35: 221-2.
37. Flanders KC, Thompson NL, Cissel DS, et al Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes. J Cell Biol. 1989; 108: 653-60.
38. De Groot CJ, Montagne L, Barten AD, et al Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. J Neuropathol Exp Neurol. 1999; 58: 174-87.
39. Aronica E, Leenstra S, Jansen GH, et al Expression of brain-derived neurotrophic factor and tyrosine kinase B receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocalization with N-methyl-D-aspartic acid receptor. Acta Neuropatho. 2001; 101: 383-92.
40. Rose K, Goldberg MP, Choi DW. Cytotoxicity in murine neocortical cell cultures. In: Tyson CA, Frazier J, editors. Methods in toxicology. In vitro biological system. San Diego San Diego Academics; 1992. pp. 46-60.
41. Trettel F, Rigamonti D, Hilditch-Maguire P, et al Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet. 2000; 9: 2799-809.
42. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25: 402-8.
43. Maat-Schieman M, Roos R, Losekoot M, et al Neuronal intranuclear and neuropil inclusions for pathological assessment of Huntington's disease. Brain Pathol. 2007; 17: 31-7.
44. Zuccato C, Ciammola A, Rigamonti D, et al Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001; 293: 493-8.
45. Zuccato C, Tartari M, Crotti A, et al Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003; 35: 76-83.
46. Gauthier LR, Charrin BC, Borrell-Pagès M, et al Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004; 118: 127-38.
47. del Toro D, Canals JM, Ginés S, et al Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J Neurosci. 2006; 26: 12748-57.
48. Bemelmans AP, Horellou P, Pradier L, et al Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther. 1999; 10: 2987-97.
49. Pérez-Navarro E, Arenas E, Marco S, et al Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur J Neurosci. 1999; 11: 241-9.
50. Duan W, Guo Z, Jiang H, et al Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA. 2003; 100: 2911-6.
51. Kells AP, Fong DM, Dragunow M, et al AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther. 2004; 9: 682-8.
52. Borrell-Pagès M, Canals JM, Cordelières FP, et al Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest. 2006; 116: 1410-24.
53. McBride JL, During MJ, Wuu J, et al Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003; 181: 213-23.
54. McBride JL, Ramaswamy S, Gasmi M, et al Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA. 2006; 103: 9345-50.
55. Lynch G, Kramar EA, Rex CS, et al Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci. 2007; 27: 4424-34.
56. Pineda JR, Rubio N, Akerud P, et al Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther. 2007; 14: 118-28.
57. DeMarch Z, Giampà C, Patassini S, et al Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Disease. 2008; 30: 375-87.
58. Gharami K, Xie Y, An JJ, et al Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem. 2008; 105: 369-79.
59. Conforti P, Ramos C, Apostol BL, et al Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci. 2008; 39: 1-7.
60. Ferrer I, Goutan E, Marín C, et al Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000; 866: 257-61.
61. Zuccato C, Liber D, Ramos C, et al Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res. 2005; 52: 133-9.
62. Zuccato C, Marullo M, Conforti P, et al Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 2008; 18: 225-38.
63. Schober A, Peterziel H, von Bartheld CS, et al GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol Dis. 2007; 25: 378-91.
64. Sometani A, Kataoka H, Nitta A, et al Transforming growth factor-beta1 enhances expression of brain-derived neurotrophic factor and its receptor, TrkB, in neurons cultured from rat cerebral cortex. J Neurosci Res. 2001; 66: 369-76.
65. Lu J, Wu Y, Sousa N, et al SMAD pathway mediation of BDNF and TGF beta 2 regulation of proliferation and differentiation of hippocampal granule neurons. Development. 2005; 132: 3231-42.
66. Harris GJ, Codori AM, Lewis RF, et al Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain. 1999; 122: 1667-78.
67. Tai YF, Pavese N, Gerhard A, et al Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007; 130: 1759-66.
68. Björkqvist M, Wild EJ, Thiele J, et al A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008; 205: 1869-77.
69. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009; 8: 765-74.
70. Squitieri F, Falleni A, Cannella M, et al Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm. 2010; 117: 77-83.
71. Shull MM, Ormsby I, Kier AB, et al Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992; 359: 693-9.
72. Van Raamsdonk JM, Murphy Z, Slow EJ, et al Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet. 2005; 14: 3823-35.
73. Ferrante RJ, Andreassen OA, Jenkins BG, et al Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000; 20: 4389-97.
74. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 1999; 38: 1431-76.
75. Mizuta I, Ohta M, Ohta K, et al Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett. 2001; 310: 117-20.
76. Jiang Y, McLennan IS, Koishi K, et al Transforming growth factor-beta 2 is anterogradely and retrogradely transported in motoneurons and up-regulated after nerve injury. Neuroscience. 2000; 97: 735-42.
77. Wyss-Coray T. Tgf-Beta pathway as a potential target in neurodegeneraation and Alzheimer's. Curr Alzh Res. 2006; 3: 191-5.
78. Vivien D, Ali C. Transforming growth factor-β signalling in brain disorder. Cytokine Growth Factor Rev. 2006; 17: 121-8.
79. Brionne TC, Tesseur I, Masliah E, et al Loss of TGF-β1 leads to increate neuronal cell death and microgliosis in mouse brain. Neuron. 2003; 40: 1133-45.
80. Zhu Y, Ahlemeyer B, Bauerbach E, et al TGF-beta1 inhibits caspase 3 activation and neuronal apoptosis in rat hippocampal cultures. Neurochem Int. 2001; 38: 227-35.
81. Prehn JH, Bindokas VP, Jordan J, et al Protective effect of transforming growth factor-beta1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol. Pharmacol. 1996; 49: 319-28.
82. Zhu Y, Yang GY, Ahlemeyer B, et al Transforming growth factor-beta1 increases Bad phosphorylation and protects neurons against damage. J Neurosci. 2002; 22: 3898-909.
83. Zhu Y, Culmsee C, Klumpp S, et al Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase 1, 2 signaling pathways. Neuroscience. 2004; 123: 897-906.
84. Datto MB, Li Y, Panus JF, et al Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 1995; 92: 5545-9.
85. Ravitz MJ, Yan S, Dolce C, et al Differential regulation of p27 and cyclin D1 by TGF-beta and EGF in C3H 10T1/2 mouse fibroblasts. J Cell Physiol. 1996; 168: 510-20.
86. Freeman RF, Estus S, Johnson EM Jr. Analysis of cell-related gene expression in postmitotic neurons: selective induction of cyclin D1 during programmed cell death. Neuron. 1994; 12: 343-55.
87. Herrup K, Busser JC. The induction of multiple cell cycle events precedes target-related neuronal death. Development. 1995; 121: 2385-95.
88. Copani A, Uberti D, Sortino MA, et al Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path Trends Neurosci. 2001; 24: 25-31.
89. Curtis MA, Penney EB, Pearson AG, et al Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci USA. 2003; 100: 9023-7.
90. Akashiba H, Ikegaya Y, Nishiyama N, et al Differential involvement of cell cycle reactivation between striatal and cortical neurons in cell death induced by 3-nitropropionic acid. J Biol Chem. 2008; 283: 6594-606.
91. Yamagata K, Andreasson KI, Kaufmann WE, et al Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993; 11: 371-86.
92. Adams J, Collaço-Moraes Y, de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem. 1996; 66: 6-13.
93. Tocco G, Freire-Moar J, Schreiber SS, et al Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol. 1997; 144: 339-49.